Core Business :
Research and Development of treatments for skeletal disorders and other bone and cartilage diseases.
Main Markets :
Pharmaceutical Companies.
Overview :
PROCHON BIOTECH LTD. is a privately owned biotechnology company founded in 1997 with the aim of finding a cure for Achondroplasia, the most common form of short-limbed dwarfism. The company has since evolved into a major player in the discovery and development of innovative growth factor-based therapies in regenerative medicine and orthopedics. PROCHON aims to transform the clinical focus of orthopedics from traditional metal implants, plates, and nails to biologically based products or orthobiologics for tissue regeneration and repair.
PROCHON’s therapeutic approach stems from its proprietary know-how in growth factors, particularly Fibroblast Growth Factors (FGF), their receptors and signaling networks (the FGF System). These are key regulators of tissue growth, regeneration and repair and are critically involved in human pathology. PROCHON designs therapeutics that modulate the FGF system focusing on treatments for bone and cartilage disorders.
Core Technologies: Interdisciplinary expertise has enabled PROCHON to develop a versatile platform for generation of proprietary modulators of the FGF system and for manipulation of their specific target cells. These modulators include tailor-made FGF variants as well as receptor specific antagonists, including small molecule tyrosine kinase inhibitors and human recombinant neutralizing antibodies. These are selected through tissue-specific cell-based high throughput screening assays, organ cultures and disease models.
Development Programs and Products:
Novel FGF formulations for bone fractures, bone loss and spine fusion
Drug therapy for short-limbed dwarfism
2nd generation autologous cartilage implants, targeting large market indications such as osteoarthritis, for the treatment of acute and chronic joint lesions. The first generation cartilage product, BioCart(TM), marketed through ProChon’s wholly owned subsidiary CTI, was approved and launched in Israel in 1998 and in Europe in 2000.
Market & Business Opportunities:
Orthobiologics represent a multi-billion dollar market potential. Prochon expects to expand market opportunities by applying its core technologies and leads to other clinical indications in regenerative medicine such as osteoporosis.
ProChon offers multiple partnering, licensing and business opportunities for developing and commercializing its novel therapeutics.